Metastatic colorectal cancer (mCRC) treatment patterns of the first 531 enrolled patients

Data presented at the ESMO Congress 2022

JB Bachet,1 C Pinto,2 G Bodoky,3 F Marti Marti,4 A Mitroshkin,5 E Choucair,6 M Fazilleau,6 A Sullivan,7 R Garcia-Carbonero,8 M Koopman9

1. Sorbonne Université, Service d’hépato-Gastro-Entérologie, Groupe Hospitalier Pitié Salpêtrière, APHP, Paris, France; 2. Medical Oncology, Clinical Cancer Centre Azienda USL – IRCCS di Reggio Emilia – Viale Risorgimento, 80 42123 Reggio Emilia, Italy; 3. Dél-Pesti Centrumkórház Szent László Telephely Albert Flórián út 5–7 1097 Budapest, Hungary; 4. The Christie NHS Foundation Trust, Manchester, UK; 5. Klinikum Freudenstadt, akademisches Lehrkrankenhaus der Universität Tübingen, Karl-von-Hahn str. 120, 72250 Freudenstadt, Germany; 6. Global Medical and Patient Affairs Servier, Suresnes, France; 7. Servier Pharmaceuticals, Boston, MA, USA; 8. Hospital Universitario Doce de Octubre Imas12, UCM, Av. De Córdoba s/n, 28041 Madrid, Spain; 9. University Medical Centre Utrecht, Utrecht University Heidelberglaan 100 3584 CX Utrecht, the Netherlands.

PROMETCO: Study background and aim

back to top

  • Tumor shrinkage and disease control with preservation or improvement in quality of life are the primary treatment goals for patients with unresectable mCRC1

  • When not possible, emphasis lies in avoidance of rapid disease evolution, and prolonging survival1

  • Advances in mCRC treatment have now improved median overall survival to 30 months in clinical trials1

  • PROMETCO (NCT03935763) is the first international, prospective real-world study to investigate the continuum of care in the mCRC patient population, collecting data on all patients regardless of treatment or age

Aim: To present real-world treatment patterns for metastatic disease, up to fourth line, for the first 531 patients enrolled in the PROMETCO study, as of October 1, 2021

  • Inclusion criteria: Adult patients with two disease progressions since the first diagnosis of metastatic disease, suitable to receive subsequent treatment

mCRC, metastatic colorectal cancer.
1. Van Cutsem E, et al. Ann Oncol. 2016;27:1386–422.

Baseline characteristics in PROMETCO

back to top

Biomolecular status

Age and sex


Disease characteristics

Baseline treatment/surgery

Real-world treatment patterns prior to enrollment in PROMETCO

back to top


First line

Second line

Third line

Fourth line


back to top

Preliminary data from the PROMETCO study provide a greater understanding of the population and key insights into the treatments received by patients with mCRC in clinical practice

In first and second line, most of the patients received CT doublet/triplet + anti-VEGF/EGFR. This is in line with treatment guidelines1

Maintenance and reintroduction were mainly represented in first line, whereas rechallenge was marginally higher in third and fourth lines, versus other lines

Sixty-eight percent of patients received FTD/TPI in third-line treatment, and 43% received regorafenib in fourth line. In-depth analysis is planned to better understand the third- and fourth-line treatment allocation (based on access to treatment options locally)

Median time between mCRC diagnosis and PROMETCO inclusion was 23 months, while median total treatment duration before inclusion was 13.3 months, therefore suggesting the use of treatment breaks in the real world

CT, chemotherapy; EGFR, epidermal growth factor receptor; FTD/TPI, trifluridine/tipiracil; mCRC, metastatic colorectal cancer; VEGF, vascular endothelial growth factor.
1. Van Cutsem E, et al. Ann Oncol. 2016;27:1386–422.


back to top